Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

AMM BeenTiktak; K. Williams; HM Vrehen; J Richens; D Aldam; AM vanLoon; C Loveday; CAB Boucher; P Ward; IVD Weller; JCC Borleffs

Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

AMM BeenTiktak, K. Williams, HM Vrehen, J Richens, D Aldam, AM vanLoon, C Loveday, CAB Boucher, P Ward, IVD Weller, JCC Borleffs

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

24 Downloads (Pure)

Abstract

Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4(+) cell counts of between 200 and 750 cells per mm(3). Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4(+) cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.

Original language	English
Pages (from-to)	2664-2668
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	40
Issue number	11
Publication status	Published - Nov-1996
Externally published	Yes

Keywords

REVERSE-TRANSCRIPTASE INHIBITOR
NONNUCLEOSIDE INHIBITORS
TYPE-1 REPLICATION
ZIDOVUDINE
COMBINATION
RESISTANCE
THERAPY
HIV-1
L-697,661
U-87201E

Access to Document

Antimicrob. Agents Chemother.-1996-Been-Tiktak-2664-8Final publisher's version, 196 KB

http://aac.asm.org/content/40/11/2664.full.pdf+html

Handle.net

Persistent link

Cite this

BeenTiktak, AMM., Williams, K., Vrehen, HM., Richens, J., Aldam, D., vanLoon, AM., Loveday, C., Boucher, CAB., Ward, P., Weller, IVD., & Borleffs, JCC. (1996). Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals. Antimicrobial Agents and Chemotherapy, 40(11), 2664-2668. http://aac.asm.org/content/40/11/2664.full.pdf+html

@article{2f73c2946d764d519b39a5fd6f95f979,

title = "Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals",

abstract = "Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4(+) cell counts of between 200 and 750 cells per mm(3). Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4(+) cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.",

keywords = "REVERSE-TRANSCRIPTASE INHIBITOR, NONNUCLEOSIDE INHIBITORS, TYPE-1 REPLICATION, ZIDOVUDINE, COMBINATION, RESISTANCE, THERAPY, HIV-1, L-697,661, U-87201E",

author = "AMM BeenTiktak and K. Williams and HM Vrehen and J Richens and D Aldam and AM vanLoon and C Loveday and CAB Boucher and P Ward and IVD Weller and JCC Borleffs",

year = "1996",

month = nov,

language = "English",

volume = "40",

pages = "2664--2668",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "AMER SOC MICROBIOLOGY",

number = "11",

}

BeenTiktak, AMM, Williams, K, Vrehen, HM, Richens, J, Aldam, D, vanLoon, AM, Loveday, C, Boucher, CAB, Ward, P, Weller, IVD & Borleffs, JCC 1996, 'Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals', Antimicrobial Agents and Chemotherapy, vol. 40, no. 11, pp. 2664-2668. <http://aac.asm.org/content/40/11/2664.full.pdf+html>

TY - JOUR

T1 - Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

AU - BeenTiktak, AMM

AU - Williams, K.

AU - Vrehen, HM

AU - Richens, J

AU - Aldam, D

AU - vanLoon, AM

AU - Loveday, C

AU - Boucher, CAB

AU - Ward, P

AU - Weller, IVD

AU - Borleffs, JCC

PY - 1996/11

Y1 - 1996/11

N2 - Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4(+) cell counts of between 200 and 750 cells per mm(3). Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4(+) cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.

AB - Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4(+) cell counts of between 200 and 750 cells per mm(3). Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4(+) cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.

KW - REVERSE-TRANSCRIPTASE INHIBITOR

KW - NONNUCLEOSIDE INHIBITORS

KW - TYPE-1 REPLICATION

KW - ZIDOVUDINE

KW - COMBINATION

KW - RESISTANCE

KW - THERAPY

KW - HIV-1

KW - L-697,661

KW - U-87201E

M3 - Article

SN - 0066-4804

VL - 40

SP - 2664

EP - 2668

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 11

ER -

Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this